Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv